Construction of a homologous targeting exosome-based drug delivery system for colorectal cancer and evaluation of its anti-tumor efficacy

This study aimed to use the homologous targeting property of tumor-derived exosomes to construct a novel drug delivery system for SN38 and assess its enhanced therapeutic potential in colorectal cancer models. Exosomes were isolated from HT29 colorectal cancer cells (HT29-EXO) and NCM460 normal intestinal epithelial cells (NCM460-EXO) using differential ultracentrifugation, followed by characterization via nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and Western blotting (WB). The chemotherapeutic drug SN38 was subsequently loaded into the exosomes via electroporation. The homologous targeting capability of HT29-EXO was validated through both in vitro cell co-culture studies and in vivo live imaging. Finally, the antitumor efficacy of the drug-loaded exosomes (HT29-EXO+SN38) was systematically evaluated using CCK-8 cell viability assays, flow cytometry-based apoptosis analysis, and a subcutaneous xenograft mouse model. This study conclusively demonstrates the superior homologous targeting of HT29-derived exosomes, showing 1.5-fold higher in vitro binding affinity and 2-fold greater in vivo tumor accumulation compared to control exosomes (NCM460-EXO). The therapeutic formulation HT29-EXO+SN38 proved significantly more effective. In vitro, it exhibited the strongest growth inhibition, reducing cell viability to 35.79%. Flow cytometry revealed that while total apoptosis rates were comparable, HT29-EXO+SN38 induced the highest rate of late apoptosis (41.57%, p < 0.001 vs. others). These results were corroborated in vivo, where the HT29-EXO+SN38 group showed the most potent efficacy, achieving the lowest final tumor weight (182.0 ± 36.33 mg) and smallest volume (103.1 ± 36.8 mm³), with significant differences versus all other groups (p < 0.05). Utilizing homologous tumor-derived exosomes as drug carriers enhances tumor inhibition by their superior targeting of parental cells and tissues.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-04-21
DOI
https://doi.org/10.1038/s41598-026-48004-5
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Construction of a homologous targeting exosome-based drug delivery system for colorectal cancer and evaluation of its anti-tumor efficacy

Wei Zhang, Leilei Ma, xiangyu ma, shousen shi et al.
Scientific Reports
Extracellular vesicles in disease
article

Construction of a homologous targeting exosome-based drug delivery system for colorectal cancer and evaluation of its anti-tumor efficacy

Wei Zhang, Leilei Ma, xiangyu ma, shousen shi, Ke Huang
article en

Abstract

This study aimed to use the homologous targeting property of tumor-derived exosomes to construct a novel drug delivery system for SN38 and assess its enhanced therapeutic potential in colorectal cancer models. Exosomes were isolated from HT29 colorectal cancer cells (HT29-EXO) and NCM460 normal intestinal epithelial cells (NCM460-EXO) using differential ultracentrifugation, followed by characterization via nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and Western blotting (WB). The chemotherapeutic drug SN38 was subsequently loaded into the exosomes via electroporation. The homologous targeting capability of HT29-EXO was validated through both in vitro cell co-culture studies and in vivo live imaging. Finally, the antitumor efficacy of the drug-loaded exosomes (HT29-EXO+SN38) was systematically evaluated using CCK-8 cell viability assays, flow cytometry-based apoptosis analysis, and a subcutaneous xenograft mouse model. This study conclusively demonstrates the superior homologous targeting of HT29-derived exosomes, showing 1.5-fold higher in vitro binding affinity and 2-fold greater in vivo tumor accumulation compared to control exosomes (NCM460-EXO). The therapeutic formulation HT29-EXO+SN38 proved significantly more effective. In vitro, it exhibited the strongest growth inhibition, reducing cell viability to 35.79%. Flow cytometry revealed that while total apoptosis rates were comparable, HT29-EXO+SN38 induced the highest rate of late apoptosis (41.57%, p < 0.001 vs. others). These results were corroborated in vivo, where the HT29-EXO+SN38 group showed the most potent efficacy, achieving the lowest final tumor weight (182.0 ± 36.33 mg) and smallest volume (103.1 ± 36.8 mm³), with significant differences versus all other groups (p < 0.05). Utilizing homologous tumor-derived exosomes as drug carriers enhances tumor inhibition by their superior targeting of parental cells and tissues.

Scientific Reports
Xinjiang Medical University (CN), Tumor Hospital of Xinjiang Medical University (CN), Luoyang Central Hospital Affiliated to Zhengzhou University (CN)
Good health and well-being
Openalex Percentile: Top 9%
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.